Policymakers

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care

World Cup Health Guidance Turns Football Into a Public-Health Test

What happens when surgeons no longer need to be in the same country as their patients?

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.

Ebola Control Hits the Trust Test

The WHO’s first stroke resolution turns a clinical problem into a political one

The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
